Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-05

FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Escitalopram Oxalate (escitalopram) by Exelan Pharmaceuticals Inc. under ANDA078604.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Escitalopram Oxalate (escitalopram oxalate)

Snippet

SUPPL AP for ESCITALOPRAM OXALATE (ESCITALOPRAM)